Clinical efficacy, safety, and pharmacokinetic profile of bosakitug (BSI-045B), an anti-thymic stromal lymphopoietin (TSLP) mAb in a phase 2 study of moderate and severe atopic dermatitis subjects

Authors
Category Primary study
JournalBritish Journal of Dermatology
Year 2024
This article has no abstract
Epistemonikos ID: 09fa19601fbc72dee011d7d734e8d407f9b746c7
First added on: Feb 18, 2025